Gastroesophageal reflux disease (GERD) is common among the American population and increasing in prevalence, with obesity being implicated as one of the strongest risk factors for its development. Little is known about the effects of currently prescribed anti-obesity medications on GERD symptoms. This review aims to explore the current literature on FDA-approved and off-label anti-obesity pharmacotherapy with respect to their influence on GERD and interactions with commonly prescribed GERD medications.
Maret-OudaJMarkarSRLagergrenJ. Gastroesophageal reflux disease: a review. JAMA. 2020;324(24):2536-2547.
2.
KatzkaDAKahrilasPJ. Advances in the diagnosis and management of gastroesophageal reflux disease. BMJ. 2020;371:m3786.
3.
EusebiLHRatnakumaranRYuanYSolaymani-DodaranMBazzoliFFordAC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430-440.
El-SeragHBSweetSWinchesterCCDentJ. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-880.
6.
DivinoVRamasamyAAnupindiVR, et al. Complication-specific direct medical costs by body mass index for 13 obesity-related complications: a retrospective database study. J Manag Care Spec Pharm. 2021;27(2):210-222.
7.
KaltenbachTCrockettSGersonLB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166(9):965-971.
8.
RichterJERubensteinJH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):267-276.
ElangovanAShahRSmithZL. Pharmacotherapy for obesity-trends using a population level national database. Obes Surg. 2021;31(3):1105-1112.
11.
GaddeKMAtkinsKD. The limits and challenges of antiobesity pharmacotherapy. Expert Opin Pharmacother. 2020;21(11):1319-1328.
12.
XiaYKeltonCMGuoJJBianBHeatonPC. Treatment of obesity: pharmacotherapy trends in the United States from 1999 to 2010. Obesity. 2015;23(8):1721-1728.
13.
KiortsisDN. A review of the metabolic effects of controlled-release phentermine/topiramate. Hormones. 2013;12(4):507-516.
14.
SweetingANTabetECatersonIDMarkovicTP. Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate. Diabetes Metab Syndr Obes. 2014;7:35-44.
LiZMaglioneMTuW, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532-546.
17.
KimKKChoHJKangHCYounBBLeeKR. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J. 2006;47(5):614-625.
18.
HornbyPJAbrahamsTP. Central control of lower esophageal sphincter relaxation. Am J Med. 2000;108(Suppl 4a):90S-98S.
19.
DaneschvarHLAronsonMDSmetanaGW. FDA-Approved anti-obesity drugs in the United States. Am J Med. 2016;129(8):879.e1-879.e6.
20.
RichardDFerlandJLalondeJSamsonPDeshaiesY. Influence of topiramate in the regulation of energy balance. Nutrition. 2000;16(10):961-966.
21.
AllisonDBGaddeKMGarveyWT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20(2):330-342.
22.
GaddeKMAllisonDBRyanDH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352.
23.
SmithSMMeyerMTrinkleyKE. Phentermine/topiramate for the treatment of obesity. Ann Pharmacother. 2013;47(3):340-349.
24.
GarveyWTRyanDHLookM, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297-308.
CiccaglioneAFMarzioL. Effect of acute and chronic administration of the GABAB agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut. 2003;52(4):464-470.
27.
DuttaUArmstrongD. Novel pharmaceutical approaches to reflux disease. Gastroenterol Clin North Am. 2013;42(1):93-117.
28.
BillesSKSinnayahPCowleyMA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1-11.
29.
SinghAKSinghR. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol. 2020;13(1):53-64.
30.
GreenwayFLFujiokaKPlodkowskiRA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605.
31.
ApovianCMAronneLRubinoD, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21(5):935-943.
32.
LeppertW. The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities. Contemp Oncol. 2012;16(2):125-131.
33.
McNicolEBoyceDBSchumannRCarrD. Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials. Pain Med. 2008;9(6):634-659.
34.
CandyBJonesLVickerstaffVLarkinPJStoneP. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care. Cochrane Database Syst Rev. 2018;6:CD006332.
SavilampiJMagnusonAAhlstrandR. Effects of remifentanil on esophageal motility: a double-blind, randomized, cross-over study in healthy volunteers. Acta Anaesthesiol Scand. 2015;59(9):1126-1136.
37.
ScarpelliniEPauwelsAVosRRommelNTackJ. Effect of methylnaltrexone and naloxone on esophageal motor function in man. Neurogastroenterol Motil. 2017;29(3):e12938.
38.
YanovskiSZYanovskiJA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74-86.
39.
FilippatosTDDerdemezisCSGaziIFNakouESMikhailidisDPElisafMS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Safety. 2008;31(1):53-65.
40.
O’DonovanDHorowitzMRussoA, et al. Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes. Diabetologia. 2004;47(12):2208-2214.
41.
GoedeckeJHBarsdorfMBeglingerCLevittNSLambertEV. Effects of a lipase inhibitor (orlistat) on cholecystokinin and appetite in response to a high-fat meal. Int J Obes Relat Metab Disord. 2003;27(12):1479-1485.
42.
O’NeilPMBirkenfeldALMcGowanB, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-649.
43.
Pi-SunyerXAstrupAFujiokaK, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22.
44.
WaddenTAHollanderPKleinS, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2015;39(1):187-251.
45.
DaviesMJBergenstalRBodeB, et al. Efficacy of liraglutide for weight loss among patients with type 2 Diabetes: the SCALE Diabetes randomized clinical trial. JAMA. 2015;314(7):687-699.
46.
FlintARabenAErsbøllAKHolstJJAstrupA. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord. 2001;25(6):781-792.
47.
van CanJSlothBJensenCBFlintABlaakEESarisWH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes. 2014;38(6):784-793.
48.
HalawiHKhemaniDEckertD, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol. 2017;2(12):890-899.
49.
MaselliDBCamilleriM. Effects of GLP-1 and its analogs on gastric physiology in Diabetes mellitus and obesity. Adv Exp Med Biol. 2021;1307:171-192.
50.
ModiRRyePCawseySBirchDWSharmaAM. Liraglutide effects on upper gastrointestinal investigations: implications prior to bariatric surgery. Obes Surg. 2018;28(7):2113-2116.
51.
PicheTdes VarannesSBSacher-HuvelinSHolstJJCuberJCGalmicheJP. Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology. 2003;124(4):894-902.
52.
QuastDRSchenkerNMengeBANauckMAKapitzaCMeierJJ. Effects of Lixisenatide versus Liraglutide (short- and long-acting GLP-1 receptor agonists) on esophageal and gastric function in patients with type 2 diabetes. Diabetes Care. 2020;43(9):2137-2145.
53.
NoguchiYKatsunoHUenoA, et al. Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database. J Pharm?Health Care?Sci. 2018;4:15.
54.
GaddeKMKoppingMFWagnerHrYonishGMAllisonDBBrayGA. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med. 2012;172(20):1557-1564.
55.
GaddeKMYonishGMFoustMSWagnerHR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry. 2007;68(8):1226-1229.
56.
SeifarthCSchehlerBSchneiderHJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121(1):27-31.
57.
YuxinHCuipingJWenT, et al. Comparison of gastrointestinal adverse events with different doses of metformin in the treatment of elderly people with type 2 diabetes. J Clin Pharm Ther. 2020;45(3):470-476.
58.
HibmaJEZurAACastroRA, et al. The effect of Famotidine, a MATE1-selective inhibitor, on the pharmacokinetics and pharmacodynamics of Metformin. Clin Pharmacokinet. 2016;55(6):711-721.
59.
DingYJiaYSongY, et al. The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects. Eur J Clin Pharmacol. 2014;70(2):141-146.
60.
KimAChungIYoonSH, et al. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metab Dispos. 2014;42(7):1174-1179.
ZhangFXuSTangLPanXTongN. Acarbose with comparable glucose-lowering but superior weight-loss efficacy to dipeptidyl peptidase-4 inhibitors: a systematic review and network meta-analysis of randomized controlled trials. Front Endocrinol. 2020;11:288.
63.
SchnellOWengJSheuWH, et al. Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: results of a worldwide, non-interventional, observational study data pool. J Diabetes Complications. 2016;30(4):628-637.
64.
ScarpelliniEArtsJKaramanolisG, et al. International consensus on the diagnosis and management of dumping syndrome. Nat Rev Endocrinol. 2020;16(8):448-466.
65.
van BeekAPEmousMLavilleMTackJ. Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management. Obes Rev. 2017;18(1):68-85.
66.
YuAQLeJHuangWT, et al. The effects of acarbose on non-diabetic overweight and obese patients: a meta-analysis. Adv Ther. 2021;38(2):1275-1289.
67.
HolmbäckUForslundAGrudénS, et al. Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity. Obes Sci Pract. 2020;6(3):313-323.
68.
HaunerHPetzinnaDSommerauerBToplakH. Effect of acarbose on weight maintenance after dietary weight loss in obese subjects. Diabetes Obes Metab. 2001;3(6):423-427.
69.
SchmitzOBrockBRungbyJ. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes. 2004;53(Suppl 3):S233-S238.
70.
DunicanKCAdamsNMDesiletsAR. The role of pramlintide for weight loss. Ann Pharmacother. 2010;44(3):538-545.
71.
AronneLFujiokaKArodaV, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92(8):2977-2983.
72.
SamsomMSzarkaLACamilleriMVellaAZinsmeisterARRizzaRA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol. 2000;278(6):G946-G951.
73.
VellaALeeJSCamilleriM, et al. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil. 2002;14(2):123-131.
74.
BrownEWildingJPHBarberTMAlamUCuthbertsonDJ. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities. Obes Rev. 2019;20(6):816-828.
75.
HollanderPBaysHERosenstockJ, et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care. 2017;40(5):632-639.
